Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals is currently in the commercial launch phase for IMPAVIDO, which is expected to contribute to revenue in September 2026. The stock has experienced significant recent volatility and high valuation concerns following a strong year-to-date performance.
Eton Pharmaceuticals is scheduled to begin commercialization of the FDA-approved orphan drug IMPAVIDO in September 2026. This launch is a key component of the company's 2026 growth strategy and revenue expansion.
Eton Pharmaceuticals Press ReleaseRecent SEC filings indicate substantial selling of company shares by insiders, including the CEO, throughout August 2026. Such high-volume selling by management can sometimes signal a lack of confidence in further short-term upside or profit-taking after a significant stock rally.
Benzinga